[A24-24] Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V
Last updated 03.06.2024
Project no.:
A24-24
Commission:
Commission awarded on 01.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adults with insomnia characterized by symptoms present for at least 3 months and considerable impact on daytime functioning.
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-24_en
| Project no. | Title | Status |
|---|---|---|
| A22-123 | Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V | Commission completed |